BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say

Reuters

Feb 04

** Shares of drug developer Compass Pathways CMPS.O fall 3.6% to $6.36

** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression

** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants

** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA

** The company did not immediately respond to a Reuters request for comment

** Reuters could not immediately verify the report

** Stock was up 82.5% in 2025

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608395719"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608395719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608395719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608395719","market":"us","top_or_hot":-1,"title":"BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say</title></head><body><p>** Shares of drug developer Compass Pathways <span>CMPS.O</span> fall 3.6% to $6.36 </p><p>** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression </p><p>** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants</p><p>** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA </p><p>** The company did not immediately respond to a Reuters request for comment</p><p>** Reuters could not immediately verify the report </p><p>** Stock was up 82.5% in 2025  </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say</title></head><body><p>** Shares of drug developer Compass Pathways <span>CMPS.O</span> fall 3.6% to $6.36 </p><p>** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression </p><p>** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants</p><p>** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA </p><p>** The company did not immediately respond to a Reuters request for comment</p><p>** Reuters could not immediately verify the report </p><p>** Stock was up 82.5% in 2025  </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL4N3Z01WA:1","article_id":"2608395719","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608395719","pubTimestamp":1770220531,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say** Shares of drug developer Compass Pathways CMPS.O fall 3.6% to $6.36 ** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression ** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA ** The company did not immediately respond to a Reuters request for comment** Reuters could not immediately verify the report ** Stock was up 82.5% in 2025    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPS":"COMPASS Pathways plc"},"translate_title":"嗡嗡声-指南针路径下降；媒体报道称，其迷幻疗法的快速审查受阻","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say** Shares of drug developer Compass Pathways CMPS.O fall 3.6% to $6.36 ** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression ** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA ** The company did not immediately respond to a Reuters request for comment** Reuters could not immediately verify the report ** Stock was up 82.5% in 2025   (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}